Last reviewed · How we verify
IBI306
IBI306 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
IBI306 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Gastric cancer, Esophageal cancer.
At a glance
| Generic name | IBI306 |
|---|---|
| Sponsor | Innovent Biologics (Suzhou) Co. Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
IBI306 is a humanized monoclonal antibody targeting programmed death receptor 1 (PD-1). By blocking PD-1, the drug prevents tumor cells from suppressing T cell-mediated immunity, allowing the immune system to recognize and attack cancer cells more effectively. This mechanism is similar to other checkpoint inhibitors in clinical use.
Approved indications
- Non-small cell lung cancer
- Gastric cancer
- Esophageal cancer
Common side effects
- Fatigue
- Decreased appetite
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Infusion-related reactions
Key clinical trials
- IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia (PHASE3)
- A Study of IBI306 in Participants With Hypercholesterolemia (PHASE3)
- Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia (PHASE2)
- Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers (PHASE1)
- Safety and Efficacy of IBI306 in HeFH Patients (PHASE3)
- A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia (PHASE2, PHASE3)
- Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia (PHASE3)
- Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IBI306 CI brief — competitive landscape report
- IBI306 updates RSS · CI watch RSS
- Innovent Biologics (Suzhou) Co. Ltd. portfolio CI